Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
INMD · against 1,336 other Healthcare companies
Ranked #44 of 1,337 · scores higher than 96% of peers
Bars: peers in each 10-point band of the valuation score141 peers with a valuation score of 90–100, including INMD · Click a bar to see the companies
Mainly thanks to its EBITDA yield, free cash flow yield and earnings yield, which are stronger than most Healthcare peers.
| Metric | INMD | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 1,287 reported | 8.6% | 1.5% | 92% | 30% | |
| EBITDA yieldHigher is better · 1,357 reported | 21.2% | 4.2% | 95% | 50% | |
| Free cash flow yieldHigher is better · 711 reported | 10.2% | -1.0% | 93% | 20% | |
| Book yieldHigher is better · 1,306 reported | 75.9% | 37.9% | 79% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 1.1B HKD (≈$146M) | 99 | 72 | |
| 1 | 14.2B HKD (≈$1.8B) | 99 | 64 | |
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 44 | 595M USD | 96 | 97 | |
| 44 | 188M CHF (≈$216M) | 96 | 74 | |
| 44 | 433M USD | 96 | 81 | |
| 44 | 289M USD | 96 | 57 | |
| 44 | 810M USD | 96 | 69 | |
| 44 | 578M USD | 96 | 73 | |
| 44 | 2.1B USD | 96 | 96 | |
| 44 | 1.2B USD | 96 | 75 | |
| 44 | 1.3B BRL (≈$238M) | 96 | 77 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score